Additionally, our research highlights promising therapeutic strategies for patients in advanced phases of CML, utilizing readily repurposable targeted agents (proteasome or Aurora‐A inhibitor) specifically in a context characterized by SETD2 and H3K36me3 deficiency. Here, SETD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.